Evidence map›Paper›PMID 24899309›Full record

ReviewNature2014

Pro-resolving lipid mediators are leads for resolution physiology.

Charles N Serhan

3 registry-linked trialsOpen access · greenAbstract readReview
In one paragraph

Review in Nature, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 1,714 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1,714citing papers in PubMed, 3 pooled it
142.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02683850 early_phase1completednot on this mapstarted 2016, after this paper: background citation

Influence of an Omega-3 SPM Supplement on Quality of Life

TypeinterventionalSponsorNational University of Natural MedicineRan2016 to 2016Enrolled44ConditionsChronic PainArmsOmega-3 SPM™ softgel
NCT02719665 nacompletednot on this mapstarted 2016, after this paper: background citation

THE OMEGA-SPM-DOSE and OMEGA-SPM-PAD: Specialized Pro-Resolving Mediators in Patients With Peripheral Artery Disease

TypeinterventionalSponsorUniversity of California, San FranciscoRan2016 to 2020Enrolled30ConditionsPeripheral Arterial Disease, Claudication, Claudication, Intermittent, Vascular OcclusionArmsSPM Emulsion, Dose-modality, SPM Softgel, Dose-Modality, Placebo Softgel
NCT03590769 phase1completednot on this mapstarted 2017, after this paper: background citation

Arterial Imaging of Inflammation and Resolution After Endovascular Surgery

TypeinterventionalSponsorUniversity of California, San FranciscoRan2017 to 2019Enrolled9ConditionsPeripheral Arterial Disease, Claudication, Intermittent, Claudication, PADArms18F-FDG
3 · Its place in the literature

Who cites it

1,714 citing papers in PubMed, 3 syntheses or guidelines pooled it, 2,849 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Review
  9. Transcriptional regulation and function of GPR18 in macrophage subtype specification.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  10. Article
  11. Article
  12. Maresin1 improves cardiac dysfunction via LGR6 in heatstroke.Experimental & molecular medicine · 2026
    Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Targeting triglycerides for cardiovascular risk reduction.Internal and emergency medicine · 2026
    Review
  20. Article

1,654 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Charles N SerhanCenter for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology, Perioperative and Pain Medicine, Harvard Institutes of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA.
Harvard University · US

Funding

Resolution Mechanisms in Acute Inflammation: Resolution PharmacologyP01GM095467 · NIGMS · BRIGHAM AND WOMEN'S HOSPITAL · PI SERHAN, CHARLES NICHOLAS · 2011 to 2020
$14.8M
BLOOD CELL LIPOXYGENASE PRODUCTS: FORMATION AND ACTIONR01GM038765 · NIGMS · BRIGHAM AND WOMEN'S HOSPITAL · PI SERHAN, CHARLES NICHOLAS · 1992 to 2020
$4.9M
NIGMS NIH HHS P01 GM095467NIGMS NIH HHS P01GM095467NIGMS NIH HHS R01 GM038765NIGMS NIH HHS R01GM038765
6 · The paper itself

Abstract

Advances in our understanding of the mechanisms that bring about the resolution of acute inflammation have uncovered a new genus of pro-resolving lipid mediators that include the lipoxin, resolvin, protectin and maresin families, collectively called specialized pro-resolving mediators. Synthetic versions of these mediators have potent bioactions when administered in vivo. In animal experiments, the mediators evoke anti-inflammatory and novel pro-resolving mechanisms, and enhance microbial clearance. Although they have been identified in inflammation resolution, specialized pro-resolving mediators are conserved structures that also function in host defence, pain, organ protection and tissue remodelling. This Review covers the mechanisms of specialized pro-resolving mediators and omega-3 essential fatty acid pathways that could help us to understand their physiological functions.

Indexed as

AnimalsChronic DiseaseDocosahexaenoic AcidsFatty Acids, Omega-3Fatty Acids, UnsaturatedHumansImmunityInfectionsInflammationInflammation MediatorsModels, BiologicalPainRegenerationTranslational Research, BiomedicalWound Healing7,14-dihydroxydocosa-4,8,10,12,16,19-hexaenoic acidDocosahexaenoic AcidsFatty Acids, Omega-3Fatty Acids, UnsaturatedInflammation Mediatorsresolvin D3

Identifiers

PMID24899309
PMCPMC4263681
OpenAlexW2090609282

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.